نتایج جستجو برای: neoadjuvant therapies

تعداد نتایج: 110875  

Journal: :AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science 2013
Daniel I Golden Jafi A Lipson Melinda L Telli James M Ford Daniel L Rubin

Experimental targeted treatments for neoadjuvant chemotherapy for triple-negative breast cancer are currently underway, and a current challenge is predicting which patients will respond to these therapies. In this study, we use data from dynamic contrast-enhanced MRI (DCE-MRI) images to predict whether patients with triple negative breast cancer will respond to an experimental neoadjuvant chemo...

Journal: :Radiologia 2012
R García Figueiras P Caro Domínguez R García Dorrego A Vázquez Martín A Gómez Caamaño

The outcome of treatment for rectal cancer in recent years has been improved by diverse advances in the field of surgery and in neoadjuvant oncologic therapies. Heald's introduction of the concept of the mesorectum as an anatomical unit (total mesorectal excision) in 1982 and the generalization of preoperative radiochemotherapy have improved the prognosis in a significant number of patients. Ow...

Journal: :گوارش 0
gi biasco ei derenzini em dibattista gi brandi

about 50% of all patients affected by crc develop liver metastases. surgery remains the only potentially curative strategy, but is impossible in the majority of patients. for non-resectable patients, two options are available: local treatment strategies (radiofrequency ablation and cryosurgery: alone or in combination with surgery) and chemotherapy. high rates of objective response achieved wit...

2014
Susan Tsai Laura McOlash Douglas B Evans Bryon Johnson Jill Gershan

In most patients, pancreatic ductal adenocarcinoma (PDAC) is metastatic at diagnosis and available systemic therapies have had only a modest impact on survival duration. The overwhelming majority of patients with apparent localized, operable disease have extra-pancreatic micrometastases. Cancer patients experience both systemic and intra-tumor immune suppression. Thus, it is likely that pancrea...

Journal: :Oncology 2014
Ursa Brown-Glaberman Zoneddy Dayao Melanie Royce

The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer, and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for millions of women with early-stage and advanced HER2-positive breast cancer. This review discusses the treatment of primary, nonmetastatic HER2-positive breast cancer in the adju...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2017
G Curigliano H J Burstein E P Winer M Gnant P Dubsky S Loibl M Colleoni M M Regan M Piccart-Gebhart H-J Senn B Thürlimann F André J Baselga J Bergh H Bonnefoi S Y Brucker F Cardoso L Carey E Ciruelos J Cuzick C Denkert A Di Leo B Ejlertsen P Francis V Galimberti J Garber B Gulluoglu P Goodwin N Harbeck D F Hayes C-S Huang J Huober K Hussein J Jassem Z Jiang P Karlsson M Morrow R Orecchia K C Osborne O Pagani A H Partridge K Pritchard J Ro E J T Rutgers F Sedlmayer V Semiglazov Z Shao I Smith M Toi A Tutt G Viale T Watanabe T J Whelan B Xu

The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer. Treatments were assessed in light of their intensity, duration and side-effects, seeking where appropriate to escalate or de-escalate therapies based on likely benefits as predicted by tumor stage and tumor biology....

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید